BioXcel Therapeutics, Inc.

DB:BX2 Stock Report

Market Cap: €19.2m

BioXcel Therapeutics Management

Management criteria checks 2/4

BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $4.73M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €24.08K. The average tenure of the management team and the board of directors is 7.1 years and 6.3 years respectively.

Key information

Vimal Mehta

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage21.2%
CEO tenure7.5yrs
CEO ownership0.1%
Management average tenure7.1yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vimal Mehta's remuneration changed compared to BioXcel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$153m

Dec 31 2023US$5mUS$1m

-US$179m

Sep 30 2023n/an/a

-US$212m

Jun 30 2023n/an/a

-US$203m

Mar 31 2023n/an/a

-US$187m

Dec 31 2022US$5mUS$944k

-US$166m

Sep 30 2022n/an/a

-US$137m

Jun 30 2022n/an/a

-US$122m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$9mUS$917k

-US$107m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$94m

Dec 31 2020US$10mUS$890k

-US$82m

Sep 30 2020n/an/a

-US$69m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$459k

-US$33m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018US$702kUS$423k

-US$19m

Sep 30 2018n/an/a

-US$15m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$284kUS$147k

-US$5m

Compensation vs Market: Vimal's total compensation ($USD4.73M) is above average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Vimal's compensation has increased whilst the company is unprofitable.

CEO

Vimal Mehta (63 yo)

7.5yrs

Tenure

US$4,731,147

Compensation

Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...

Leadership Team

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder7.5yrsUS$4.73m0.13%
€ 24.1k
Javier Rodriguez
Senior VP3.8yrsUS$1.12m0.056%
€ 10.7k
Richard Steinhart
Senior VP & CFO7.1yrsUS$404.00k0.047%
€ 9.1k
Frank Yocca
Senior VP & Chief Scientific Officer7.4yrsUS$1.15m0.066%
€ 12.7k
Vincent O'Neill
Executive VP and Chief of Product Development & Medical Officer7.3yrsUS$510.17k0.046%
€ 8.8k
Chetan Lathia
Senior VP and Head of Translational Medicine2.3yrsno datano data
Robert Risinger
Chief Medical Officer - Neuroscience2.8yrsno datano data

7.1yrs

Average Tenure

63yo

Average Age

Experienced Management: BX2's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder7.6yrsUS$4.73m0.13%
€ 24.1k
Steven Paul
Member of Advisory Boardno datano datano data
Peter Mueller
Independent Chairman & Lead Director7.6yrsUS$367.33k0.54%
€ 104.3k
Alan Breier
Member of Clinical Advisory Board6.3yrsno datano data
Thomas Laughren
Member of Clinical Advisory Board5.8yrsno datano data
Maurizio Fava
Member of Clinical Advisory Board5.8yrsno datano data
Stephen Marder
Member of Clinical Advisory Board6.3yrsno datano data
Sheldon Preskorn
Member of Clinical Advisory Board6.3yrsno datano data
John Krystal
Member of Clinical Advisory Board5.8yrsno datano data
Sandeep Laumas
Independent Director7.2yrsUS$329.83k0%
€ 0
Sheila Gujrathi
Member of Advisory Boardno datano datano data
George Grossberg
Member of Clinical Advisory Board6.3yrsno datano data

6.3yrs

Average Tenure

63yo

Average Age

Experienced Board: BX2's board of directors are considered experienced (6.3 years average tenure).